Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00782067 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
NCT00782067 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 116 participants.
The verdict
NCT00782067, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
Study Summary
The purpose of this study was to determine the efficacy and safety of twice daily (bid) oral midostaurin in patients with Aggressive Systemic Mastocytosis (ASM) or Mast Cell Leukemia (MCL) with or without an Associated Hematological clonal Non-Mast cell lineage Disease (AHNMD).
Interventions
- DRUG Midostaurin (PKC412)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2008-10-13 |
| Est. Completion | 2017-08-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00782067
The ClinicalTrials.gov registry entry for NCT00782067 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Midostaurin (PKC412) is the first listed.
NCT00782067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00782067 about?
NCT00782067 is a clinical study titled "Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia". The purpose of this study was to determine the efficacy and safety of twice daily (bid) oral midostaurin in patients with Aggressive Systemic Mastocytosis (ASM) or Mast Cell Leukemia (MCL) with or without an Associated Hematological clonal Non-Mast cell lineage Disease (AHNMD).
What is the current status of trial NCT00782067?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2008-10-13. Estimated completion is 2017-08-24.
What interventions are being tested in trial NCT00782067?
The interventions under investigation include: Midostaurin (PKC412) (DRUG).
Who is sponsoring clinical trial NCT00782067?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.